FIGURE

FIGURE 6

ID

ZDB-FIG-231228-135

Publication

Valencia-Sama et al., 2023 - SHP2 inhibition with TNO155 increases efficacy and overcomes resistance of ALK inhibitors in neuroblastoma

Other Figures

All Figure Page

Back to All Figure Page

FIGURE 6

Alterations in RAS-MAPK pathway associate with lorlatinib resistance. A, Abundance of specific BRAF, RAF1, and ERK2 phospho-sites identified by LC/MS-MS in Kelly-LR samples relative to Kelly-S. B, GTP pulldown (PD) of WCE lysates of Kelly-S and Kelly-LR cells. IB, immunoblot. C, Western immunoblots of Kelly-S and Kelly-LR cells treated with TNO155 (1.5 µmol/L), lorlatinib (1 µmol/L) or combination treatment for 6 hours. *, P < 0.05; **, P < 0.01; n.s., not significant.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cancer Res Commun